Biodesix: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Biodesix (NASDAQ:BDSX) reported Q4 earnings, beating estimated earnings by 9.0% with an EPS of $-0.1 versus an estimate of $-0.11. However, revenue was down $893.33 million from the same period last year. Despite beating EPS estimates in the past, such performance was previously followed by a 10.0% drop in share price the next day.
March 01, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biodesix reported a better-than-expected Q4 EPS but saw a significant decrease in revenue compared to the same period last year. Historical data shows past earnings beats were followed by a decrease in share price.
The positive EPS beat by Biodesix may initially seem favorable, but the significant drop in revenue and historical context of share price drops following earnings beats suggest a potential short-term negative impact on BDSX's stock price.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100